Published in Vaccine Weekly, March 3rd, 2004
The aim of the collaboration is to optimize the MicroPyramid platform for vaccine delivery. The MicroPyramid technology offers the possibility to effectively and painlessly administer vaccines intra-epidermally. Conventional needles are too large to do this, and transdermal patch or chemical technologies are incapable of efficiently delivering large molecules.
According to NanoPass founder Shuki Yeshurun, "There is potential that this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.